TriSalus Life Sciences (TLSI) Earnings Date & Reports

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

TLSI is expected to report earnings to fall 22.56% to -12 cents per share on November 12

TriSalus Life Sciences TLSI Stock Earnings Reports

Q3'26

Est.

$-0.12

Q2'26

Missed

by $0.01

Q4'24

Beat

by $0.08

The last earnings report on August 07 showed earnings per share of -15 cents, missing the estimate of -15 cents. With 60.10K shares outstanding, the current market capitalization sits at 288.78M.

View a ticker or compare two or three

TLSI

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for TLSI